Novo Nordisk Discloses Insider Share Transactions
Ticker: NONOF · Form: 6-K · Filed: Feb 6, 2025 · CIK: 353278
Sentiment: neutral
Topics: insider-trading, disclosure, regulation
Related Tickers: NVO
TL;DR
Novo Nordisk insiders bought/sold shares, check the filing for details.
AI Summary
On February 6, 2025, Novo Nordisk A/S disclosed transactions in its own shares by board members, executives, and associated persons. This disclosure is made in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Why It Matters
This filing provides transparency into the trading activities of company insiders, which can offer insights into their confidence in the company's future performance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of insider trading activity and does not present new financial or operational risks.
Key Players & Entities
- Novo Nordisk A/S (company) — Registrant
- Regulation No. 596/2014 (regulation) — Governing market abuse disclosures
FAQ
What type of transactions are being disclosed by Novo Nordisk?
The filing discloses transactions in Novo Nordisk shares made by the company's board members, executives, and their associated persons.
What regulation governs these disclosures?
These disclosures are made in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
When was this announcement made?
The announcement was made on February 6, 2025.
Where is Novo Nordisk A/S headquartered?
Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Is Novo Nordisk filing an annual report on Form 20-F or 40-F?
Novo Nordisk indicates it files annual reports under cover of Form 20-F.
Filing Stats: 3,551 words · 14 min read · ~12 pages · Grade level 20 · Accepted 2025-02-06 07:36:55
Filing Documents
- f6k_020625.htm (6-K) — 443KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-25-000664.txt ( ) — 583KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: February 6, 2025 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer